| The blockade of immune checkpoints in cancer immunotherapy DM Pardoll Nature reviews cancer 12 (4), 252-264, 2012 | 15215 | 2012 |
| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14223 | 2012 |
| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9968 | 2015 |
| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 9061 | 2012 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6406 | 2017 |
| STATs in cancer inflammation and immunity: a leading role for STAT3 H Yu, D Pardoll, R Jove Nature reviews cancer 9 (11), 798-809, 2009 | 4765 | 2009 |
| Immune checkpoint blockade: a common denominator approach to cancer therapy SL Topalian, CG Drake, DM Pardoll Cancer cell 27 (4), 450-461, 2015 | 4244 | 2015 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167-3175, 2010 | 3664 | 2010 |
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor … G Dranoff, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose, ... Proceedings of the National Academy of Sciences 90 (8), 3539-3543, 1993 | 3432 | 1993 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2742 | 2014 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy SL Topalian, JM Taube, RA Anders, DM Pardoll Nature Reviews Cancer 16 (5), 275-287, 2016 | 2680 | 2016 |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical cancer research 20 (19), 5064-5074, 2014 | 2600 | 2014 |
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ... Science translational medicine 4 (127), 127ra37-127ra37, 2012 | 2463 | 2012 |
| Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment H Yu, M Kortylewski, D Pardoll Nature reviews immunology 7 (1), 41-51, 2007 | 2192 | 2007 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2064 | 2018 |
| A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses S Wu, KJ Rhee, E Albesiano, S Rabizadeh, X Wu, HR Yen, DL Huso, ... Nature medicine 15 (9), 1016-1022, 2009 | 1865 | 2009 |
| Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ... Cell 162 (5), 974-986, 2015 | 1854 | 2015 |
| Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape SR Woo, ME Turnis, MV Goldberg, J Bankoti, M Selby, CJ Nirschl, ... Cancer research 72 (4), 917-927, 2012 | 1829 | 2012 |
| The Central Role of CD4+ T Cells in the Antitumor Immune Response K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, ... The Journal of experimental medicine 188 (12), 2357-2368, 1998 | 1721 | 1998 |
| Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity SL Topalian, CG Drake, DM Pardoll Current opinion in immunology 24 (2), 207-212, 2012 | 1712 | 2012 |
Elizabeth JaffeeJohns Hopkins University School of MedicineEmail verificata su jhmi.edu
